DK3608334T3 - Tatk-cdkl5-fusionsproteiner, sammensætninger, formuleringer og anvendelse deraf - Google Patents

Tatk-cdkl5-fusionsproteiner, sammensætninger, formuleringer og anvendelse deraf Download PDF

Info

Publication number
DK3608334T3
DK3608334T3 DK19179287.8T DK19179287T DK3608334T3 DK 3608334 T3 DK3608334 T3 DK 3608334T3 DK 19179287 T DK19179287 T DK 19179287T DK 3608334 T3 DK3608334 T3 DK 3608334T3
Authority
DK
Denmark
Prior art keywords
tatk
formulations
compositions
fusion proteins
cdkl5 fusion
Prior art date
Application number
DK19179287.8T
Other languages
Danish (da)
English (en)
Inventor
Elisabetta Ciani
Franco Laccone
Original Assignee
Univ Bologna Alma Mater Studiorum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bologna Alma Mater Studiorum filed Critical Univ Bologna Alma Mater Studiorum
Application granted granted Critical
Publication of DK3608334T3 publication Critical patent/DK3608334T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4737C-reactive protein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/60Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40Regulators of development
    • C12N2501/405Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11022Cyclin-dependent kinase (2.7.11.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
DK19179287.8T 2014-02-28 2015-02-27 Tatk-cdkl5-fusionsproteiner, sammensætninger, formuleringer og anvendelse deraf DK3608334T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461946280P 2014-02-28 2014-02-28
EP15736034.8A EP3110837B1 (en) 2014-02-28 2015-02-27 Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof

Publications (1)

Publication Number Publication Date
DK3608334T3 true DK3608334T3 (da) 2021-08-23

Family

ID=53539745

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15736034.8T DK3110837T3 (da) 2014-02-28 2015-02-27 Tatk-cdkl5-fusionsproteiner, sammensætninger, formule-ringer og anvendelse deraf
DK19179287.8T DK3608334T3 (da) 2014-02-28 2015-02-27 Tatk-cdkl5-fusionsproteiner, sammensætninger, formuleringer og anvendelse deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15736034.8T DK3110837T3 (da) 2014-02-28 2015-02-27 Tatk-cdkl5-fusionsproteiner, sammensætninger, formule-ringer og anvendelse deraf

Country Status (33)

Country Link
US (4) US9290746B2 (enExample)
EP (2) EP3110837B1 (enExample)
JP (2) JP6629747B2 (enExample)
KR (1) KR102307276B1 (enExample)
CN (1) CN106255706A (enExample)
AU (2) AU2015221860B2 (enExample)
BR (1) BR112016019868B1 (enExample)
CA (1) CA2940401C (enExample)
CL (1) CL2016002142A1 (enExample)
CR (1) CR20160392A (enExample)
CY (2) CY1122644T1 (enExample)
DK (2) DK3110837T3 (enExample)
DO (1) DOP2016000220A (enExample)
EA (2) EA202190727A3 (enExample)
ES (2) ES2885245T3 (enExample)
HR (2) HRP20191511T1 (enExample)
HU (2) HUE045393T2 (enExample)
IL (2) IL247481B (enExample)
LT (2) LT3110837T (enExample)
MX (2) MX392778B (enExample)
MY (1) MY181566A (enExample)
NI (1) NI201600127A (enExample)
PE (1) PE20161406A1 (enExample)
PH (1) PH12016501689A1 (enExample)
PL (2) PL3608334T3 (enExample)
PT (2) PT3608334T (enExample)
RS (2) RS62244B1 (enExample)
SG (2) SG10202000537RA (enExample)
SI (2) SI3110837T1 (enExample)
SM (2) SMT202100478T1 (enExample)
SV (1) SV2016005264A (enExample)
WO (1) WO2015128746A2 (enExample)
ZA (2) ZA201606655B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202000537RA (en) * 2014-02-28 2020-03-30 Univ Bologna Alma Mater Studiorum Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
WO2018005617A2 (en) * 2016-06-28 2018-01-04 Alma Mater Studiorum - Universitá Di Bologna TATĸ-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS, AND USE THEREOF
TW201927825A (zh) * 2017-11-30 2019-07-16 美商阿米庫斯醫療股份有限公司 Cdkl5 表現變體和cdkl5 融合蛋白
EP4028413A1 (en) 2019-09-10 2022-07-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
WO2021087282A1 (en) * 2019-10-30 2021-05-06 Amicus Therapeutics, Inc. Recombinant cdkl5 proteins, gene therapy and production methods
IT202000025423A1 (it) * 2020-10-27 2022-04-27 Ulisse Biomed S P A Uso di proteine per il trattamento di patologie associate a tossine formanti pori o a proteine virali
AU2021392642A1 (en) 2020-12-01 2023-06-22 The Trustees Of The University Of Pennsylvania Compositions and uses thereof for treatment of angelman syndrome
WO2025050032A1 (en) * 2023-08-31 2025-03-06 Ultragenyx Pharmaceutical Inc. Methods of producing cdkl5 proteins and uses of the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2815582A1 (en) * 2010-10-25 2012-05-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Treatment of mecp2-associated disorders
SG10202000537RA (en) * 2014-02-28 2020-03-30 Univ Bologna Alma Mater Studiorum Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof

Also Published As

Publication number Publication date
PH12016501689B1 (en) 2016-10-03
EP3608334B1 (en) 2021-05-19
AU2015221860B2 (en) 2019-09-12
EP3110837A2 (en) 2017-01-04
AU2015221860A1 (en) 2016-09-08
CR20160392A (es) 2017-06-12
NI201600127A (es) 2017-03-13
DOP2016000220A (es) 2016-12-15
ES2745335T3 (es) 2020-02-28
EP3608334A1 (en) 2020-02-12
SMT202100478T1 (it) 2021-09-14
BR112016019868B1 (pt) 2023-11-28
US10584318B2 (en) 2020-03-10
SV2016005264A (es) 2017-02-15
SG11201606863YA (en) 2016-09-29
HUE045393T2 (hu) 2019-12-30
US10907138B2 (en) 2021-02-02
PH12016501689A1 (en) 2016-10-03
KR102307276B1 (ko) 2021-09-30
HUE055282T2 (hu) 2021-11-29
US9944910B2 (en) 2018-04-17
WO2015128746A2 (en) 2015-09-03
PT3608334T (pt) 2021-08-25
RS62244B1 (sr) 2021-09-30
LT3608334T (lt) 2021-11-25
MY181566A (en) 2020-12-29
US20150247134A1 (en) 2015-09-03
AU2019219743A1 (en) 2019-09-19
NZ723371A (en) 2023-11-24
ES2885245T3 (es) 2021-12-13
CN106255706A (zh) 2016-12-21
EA202190727A3 (ru) 2021-11-30
IL247481A0 (en) 2016-11-30
US20200199549A1 (en) 2020-06-25
CA2940401C (en) 2022-11-29
MX2016011167A (es) 2017-04-06
IL275435A (en) 2020-08-31
PE20161406A1 (es) 2017-01-14
BR112016019868A2 (pt) 2017-10-17
KR20170002372A (ko) 2017-01-06
ZA201606655B (en) 2020-05-27
CL2016002142A1 (es) 2017-09-08
MX2020001223A (es) 2022-05-31
MX392778B (es) 2025-03-24
CY1124727T1 (el) 2022-07-22
JP2020062022A (ja) 2020-04-23
EA201691691A1 (ru) 2017-05-31
ZA201906304B (en) 2022-03-30
DK3110837T3 (da) 2019-09-16
CA2940401A1 (en) 2015-09-03
US20180327725A1 (en) 2018-11-15
PL3110837T3 (pl) 2020-04-30
JP6896050B2 (ja) 2021-06-30
AU2019219743B2 (en) 2020-10-29
JP6629747B2 (ja) 2020-01-15
WO2015128746A3 (en) 2015-11-26
US9290746B2 (en) 2016-03-22
IL247481B (en) 2020-07-30
HRP20191511T1 (hr) 2019-11-29
US20160194617A1 (en) 2016-07-07
LT3110837T (lt) 2019-10-10
SG10202000537RA (en) 2020-03-30
HRP20211324T1 (hr) 2021-11-26
PT3110837T (pt) 2019-09-12
SI3110837T1 (sl) 2019-12-31
RS59344B1 (sr) 2019-10-31
PL3608334T3 (pl) 2021-11-22
CY1122644T1 (el) 2021-03-12
IL275435B (en) 2021-07-29
JP2017507655A (ja) 2017-03-23
EA038000B1 (ru) 2021-06-22
SI3608334T1 (sl) 2021-11-30
EA202190727A2 (ru) 2021-07-30
SMT201900504T1 (it) 2019-11-13
EP3110837B1 (en) 2019-06-12

Similar Documents

Publication Publication Date Title
DK3347472T3 (da) Sammensætninger som indeholder cyp76ad1- clade polypeptider og anvendelse heraf.
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
DK3104718T3 (da) Tobaksholdig gelsammensætning
LT3240895T (lt) Kompozicijos ir būdai, skirti baltymų glikozilinimui
CL2016002569A1 (es) Anticuerpos, composiciones farmacéuticas y usos de los mismos
DK3498292T3 (da) Uspa2-proteinkonstruktioner og anvendelser deraf
DK3107562T3 (da) P97-ids-fusionsproteiner
DK3137168T3 (da) Substituerede 4-phenylpiperidiner, deres fremstilling og anvendelse
IL275435A (en) TATK – CDKL5 fusion proteins, preparations, formulations, and their uses
IL256322A (en) Improved formulations of deferasirox and methods of making the same
DK3233111T3 (da) Farmaceutisk sammensætning, der omfatter plasminogen, og anvendelser deraf
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3236934T3 (da) Farmaceutisk sammensætning, fremstilling og anvendelser deraf
IL263842A (en) Tatk -cdkl5 fusion proteins, compositions, formulations, and use thereof
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf
DK3229843T3 (da) Farmaceutisk sammensætning, præparat og anvendelser deraf
DK3383397T3 (da) Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin
DK3302483T3 (da) Farmaceutiske sammensætninger og anvendelse deraf
DK3158058T3 (da) Fusionsproteiner og bruger deraf
DK3166960T3 (da) Lav-substituerede polymyxiner og sammensætninger deraf
DK3099314T3 (da) Tolerogene sammensætninger og anvendelser deraf
DK3193952T3 (da) Sammensætning indeholdende glycosaminoglycans og proteiner
DK3322733T3 (da) Hide1-sammensætninger og fremgangsmåder